Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.
Zacks Investment Research on MSN
Investors heavily search Pfizer Inc. (PFE): Here is what you need to know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what ...
Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...
Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...
Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results